Cigna’s New Pricing Strategy: A Step Toward PBM Reform?
- Roxanne Newland, RPh
- Oct 30
- 1 min read
Cigna’s new pricing strategy raises important questions about the future of pharmacy benefit management.
Beginning in 2026, the company plans to introduce a cost-plus reimbursement model for pharmacies, followed by a 2027 rollout of technology-driven price comparisons for Commercial customers—eliminating traditional rebates in the process.
As specialty drug costs continue to rise, PBMs remain under increased scrutiny. Transparent pricing is no longer optional—it’s essential to ensuring access to clinically appropriate medications across Commercial, Medicare, and Medicaid markets.
This approach could represent a meaningful step toward reform in how prescription drugs are priced and reimbursed. But it also raises new considerations for pharmacy networks, member access, and plan sustainability.
At Rebellis Group, we help health plans navigate the operational and strategic implications of these evolving models—connecting pricing reform, Stars performance and pharmacy quality strategies to ensure long-term success.
Comments